Wells Fargo Reiterates Overweight Rating on BridgeBio Pharma (BBIO)
Tweet
Share
E-mailGet Alerts BBIO Hot Sheet
Price: $79.86 -1.66%
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wells Fargo analyst Derek Archila reiterated an Overweight rating and $76.00 price target on BridgeBio Pharma (NASDAQ: BBIO)
For an analyst ratings summary and ratings history on BridgeBio Pharma click here. For more ratings news on BridgeBio Pharma click here.
Shares of BridgeBio Pharma closed at $54.92 yesterday.
You May Also Be Interested In
- BridgeBio Pharma (BBIO) PT Raised to $106 at Canaccord
- BridgeBio Pharma (BBIO) PT Raised to $111 at JPMorgan
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
